Available evidence indicates that clozapine is the most effective antipsychotic currently used for the pharmacotherapy of schizophrenia. Unfortunately, clozapine can cause serious side effects that limit the use of the drug. The therapeutic mechanism of action of clozapine is poorly understood, and accordingly, it has been difficult to design new drugs with the advantageous therapeutic properties of clozapine. Based on hypotheses that dopaminergic and serotonergic receptor-blocking properties of clozapine account for its clinical efficacy, several novel antipsychotic drugs have been introduced recently. There is currently insufficient data to reach definitive conclusions regarding the efficacy of the newer 'atypical' antipsychotics in comparison to clozapine. However, most published studies, and general clinical impressions, suggest that none of the newer drugs are as effective as clozapine in treating patients resistant to typical antipsychotic drug therapy. The present paper briefly reviews the clinical experience with the newer 'atypical' antipsychotic drugs and then discusses clinical and preclinical data potentially relevant to mechanisms of action of clozapine in relation to the NMDA receptor hypofunction hypothesis of schizophrenia.
The introduction of clozapine for the pharmacotherapy of schizophrenia represented a significant advance in the treatment of this devastating mental illness. Clozapine is superior to typical neuroleptic drugs (eg haloperidol) in treating positive and negative symptoms, and is effective in many patients who are refractory to typical antipsychotics. [1] [2] [3] In addition, clozapine does not induce the extrapyramidal side effects (EPS) commonly caused by the typical agents. Because of these properties, clozapine was termed atypical and represents the prototype drug of this class. Although clozapine is the most efficacious antipsychotic currently available, serious side effects induced by the drug, including agranulocytosis, impose substantial limitations on its use. Concerted research and development efforts have been made to produce an antipsychotic drug with the therapeutic advantages of clozapine, without the properties contributing to its serious side effects. However, the specific pharmacological characteristics of clozapine that confer its therapeutic properties are poorly understood. Clozapine binds to a diverse number of neurotransmitter receptors (see Table 1 ) but it is unclear whether actions at specific serotonin, dopamine, or adrenergic receptors, alone or in combination, account for its clinical efficacy.
A number of specific hypotheses concerning mechanisms of action of clozapine have directed drug discovery efforts and led to clinical trials of drugs with widely different receptor-binding characteristics. The clinical experience with drugs whose development was inspired by clozapine will be briefly reviewed and then actions of clozapine and other antipsychotic drugs will be addressed in the context of the NMDA hypofunction hypothesis of schizophrenia.
Clinical experience with clozapine-inspired putative antipsychotics in relation to therapeutic mechanisms of action
One of the earliest hypotheses of clozapine's mechanism of action related to the D1 dopamine antagonistic properties of the drug. 4 Clozapine binds to D1 receptors in vitro with modest affinity (see Table 1 ) and at therapeutic doses occupies approximately 40-50% of D1 receptors in humans. 5 Based on the hypothesis that the D1 antagonistic properties of clozapine distinguished it from the typical antipsychotic drugs, selective D1 antagonists were developed as potential antipsychotic agents. Unfortunately, such drugs were not effective and there were indications that selective D1 antagonists may have even exacerbated symptoms of schizophrenia and induced extrapyramidal side effects. 6, 7 Although selective D1 antagonists were not effective, it is possible that D1 antagonistic properties of clozapine, in combination with other actions of the drug, contribute to, but are not sufficient for, its therapeutic effects.
Clozapine has relatively high affinity for 5HT2A receptors and is a potent antagonist of 5HT2A receptormediated responses in vivo. 8, 9 The hypothesis has been advanced that the combination of relatively high affinity for 5HT2A receptors, and lower affinity for D2 receptors, account for the atypical therapeutic actions of clozapine and other atypical antipsychotics. 10 The balanced D2/5HT2 hypothesis was the driving force behind development of risperidone, which is a potent D2 and 5HT2 antagonist, but with greater relative affinity for the 5HT2A receptor (Table 1) . Consistent with the receptor-binding characteristics of risperidone, high occupancy of D2 and 5HT2 receptors is observed clinically at therapeutic doses.
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Although risperidone is an effective antipsychotic agent, and has a favorable side effect profile in comparison to haloperidol, the general clinical impression has been that risperidone is not as effective as clozapine in schizophrenic patients resistant to treatment with typical antipsychotics. However, there is insufficient clinical data available to unequivocally establish the superior efficacy of clozapine relative to risperidone (for review see 3 ). Flynn et al 12 and Breier et al 13 found that clozapine was more effective than risperidone in treatment-resistant patients. However, Bondolfi et al found no difference between risperidone and clozapine in treatment-resistant patients. 14 In this latter study, certain methodological issues may have led to an overestimation of the efficacy of both clozapine and risperidone in truly resistant patients. 3 Consequently, it is difficult to infer equal efficacy of the drugs from the study of Bondolfi et al. 14 Further investigation is necessary to adequately compare the relative efficacy of risperidone and clozapine in treatment-resistant patients.
The reduced EPS side effects associated with low dose risperidone treatment (4-6 mg day −1 ), even at high levels of D2 receptor occupancy, may be due to the 5HT2A antagonistic properties of the drug. 10, 15 However, at higher doses, risperidone produces EPS, indicating that 5HT2A receptor antagonism alone cannot completely eliminate EPS associated with high D2 receptor blockade. The potential role of 5HT2A receptor antagonism in therapeutic responses to atypical antipsychotic drugs may become more apparent when data from clinical trials are available for the selective 5HT2A antagonists M100907.
Risperidone, like clozapine, has relatively high affinity for alpha-1 and alpha-2 adrenergic receptors. The potential therapeutic significance of the adrenergic receptor-blocking properties of clozapine and risperidone are uncertain. Addition of the alpha-2 antagonist idazoxan to the regime of patients treated with the typical neuroleptic fluphenazine improved treatment responses in patients refractory to treatment with fluphenazine alone. 16 However, there has been no confirmation of the effects of alpha-2 antagonists as adjuncts to typical neuroleptic treatment and it has been suggested that alpha-2 agonists may actually be useful for treating cognitive deficits of the disease. 17 Based on findings of elevated D3 dopamine receptors in drug-free schizophrenics, and a reduction in these receptors in patients treated with antipsychotics, Gurevich et al 18 have suggested that normalization of D3 receptors may be contribute to the efficacy of antipsychotic drugs. While risperidone and haloperidol are relatively potent D3 antagonists (Table 1) , the affinity of clozapine for the D3 receptor is even lower than that for the D2 receptor. Thus antagonism of D3 receptors by haloperidol and the newer 'atypical' drugs could contribute to their therapeutic actions, but it is unlikely that the antipsychotic actions of clozapine can be explained on the basis of D3 receptor blockade.
D4 dopamine receptor antagonism has also been suggested to contribute to the therapeutic action of clozapine. 19, 20 Clozapine has a relatively high affinity for the D4 receptor compared to the D2 receptor (Table 1) , which is enriched in the hippocampus and prefrontal cortex. Furthermore, a number of clinically efficacious antipsychotic drugs have high affinity for this receptor site (Table 1 ). An initial clinical study with the selective D4 antagonist L-745 870 did not demonstrate efficacy in the treatment of schizophrenia. 21, 22 However, since only one small dose was tested, it is difficult to draw firm conclusions regarding the potential utility of D4 antagonists as antipsychotic agents. 23 Several other selective D4 antagonists have shown promise in preclinical pharmacological screens [24] [25] [26] and are currently being tested in patients with schizophrenia. Results of the clinical studies could allow a more complete assessment of the efficacy of D4 antagonists in the treatment of schizophrenia.
Olanzapine is a drug closely related in chemical structure to clozapine (Figure 1) , and the two drugs have many common receptor-binding characteristics (Table 1) . Olanzapine was selected for development in large part because of its relatively potent antagonistic effects at both D2 and 5HT2A receptors. 27, 28 Like clozapine, olanzapine is more potent at 5HT2 than D2 receptors. In addition, the pharmacologic profile of olanzapine in regard to other dopaminergic, serotonergic, cholinergic, and adrenergic receptor subtypes is similar to clozapine, but there are also some notable differences (see Table 1 ). For example, clozapine has substantially higher affinity for 5HT1A and 5HT7 receptors in comparison to olanzapine. Extensive controlled studies have proven olanzapine to be an effective antipsychotic that has very low EPS liability. [29] [30] [31] [32] EPS side effects are minimal even at doses that produce D2 receptor occupancy of 70-80%. 33, 34 Although olanzapine is highly effective in many patients, clinical experience with currently suggested doses indicates that it is not as effective as clozapine in patients refractory to effects of typical antipsychotics. 35 There is insufficient clinical data for ziprasidone, quetiapine, and M-100907 to compare the efficacy of these newer atypical antipsychotics with clozapine.
Potential relationships between D2 and 5HT2 receptor occupancy and therapeutic mechanisms of atypical antipsychotic drugs
Although further studies are required to firmly establish the relative efficacy of the new generation of atypical antipsychotic drugs in comparison to clozapine, general clinical impressions suggest that clozapine has greater efficacy than new 'atypical' antipsychotic drugs. The imaging studies showing that therapeutic doses of risperidone and olanzapine produce high occupancy of D2 receptors suggest that D2 receptor antagonism could be a predominant mechanism of action of these new 'atypical' drugs. 11, 33, 36 Although clozapine does not exhibit high levels of D2 receptor occupancy as assessed by standard approaches, Seeman and Tallerico 37 have suggested that the drug can indeed occupy high levels of the D2 receptors when competing with endogenous dopamine, and not the radioligands used to assess in vivo receptor occupancy. Seeman and Tallerico 37 hypothesize that the low EPS liability for clozapine is related to its relatively low affinity for the D2 receptor and the antipsychotic efficacy is due to effective antagonism of endogenous dopamine. Although this theoretical position could explain the lack of EPS in response to clozapine treatment, it does not explain the greater efficacy of clozapine in relation to other currently used antipsychotic drugs. If a predominant action of clozapine is not D2 antagonism, this would provide an explanation for the superior efficacy of clozapine in the patients resistant to typical neuroleptics (as well as to olanzapine and risperidone), for which D2 receptor antagonism may be a predominant therapeutic mechanism of action.
The high level of 5HT2A receptor occupancy produced by 'atypical' antipsychotic drugs such as risperidone and olanzapine suggests that antagonism of this receptor may be involved in their clinical actions. 5, 11, 33, 36 Preclinical studies show that 5HT2A receptor antagonists attenuate cataleptic effects of D2 receptor antagonists. [38] [39] [40] [41] These data suggest that the 5HT2A receptor antagonism may contribute to the low EPS liability of risperidone and olanzapine, and also the recently introduced drugs quetiapine and ziprasidone.
Clozapine, risperidone and olanzapine occupy Ͼ80% of 5HT2A receptors in the therapeutic dose range in humans. 5, 11, 33, 36, 42 Although 5HT2A receptor antagonism is likely to be involved in the low EPS liability of risperidone and olanzapine, the role of this molecular action in therapeutic responses to clozapine is uncertain. If a high level of 5HT2A receptor antagonism was responsible for the efficacy of clozapine, then risperidone and olanzapine would be expected to be as effective as clozapine in treatment-resistant patients, but to date this has not been demonstrated. 3, 12, 13, 35 The available basic science and clinical data suggest that antagonistic actions at D2/D3 and 5HT2A receptors are insufficient to explain the superior therapeutic efficacy of clozapine in relation to other antipsychotic agents. Whether the combination of clozapine's actions at other serotonergic receptors (ie 5HT1A, 5HT2C, 5HT6, 5HT7) or adrenergic receptors is responsible for the drug's efficacy may become apparent when more extensive clinical data are available for ziprasidone and quetiapine, which exhibit widely varying affinities for these receptors. No definite conclusions can be reached regarding the relative efficacy of the new atypical antipsychotics, until adequately controlled clinical studies are conducted that compare the new atypical 
Potential new directions for antipsychotic drug discovery
The interaction of clozapine with a diverse array of neurotransmitter receptors complicates identification of the molecular characteristics of the drug that confer its atypical therapeutic properties. It is possible that none of the newer 'atypical' drugs have the appropriate combination and relative proportion of generally recognized pharmacological actions of clozapine at specific neurotransmitter receptors (Table 1 ). Alternatively, it is possible that a currently unrecognized neurochemical action of clozapine contributes to its therapeutic efficacy and none of the newer 'atypical' drugs have been modeled on the critical molecular property to create a drug with an efficacy profile comparable to clozapine.
As noted above, the rationale for development of the antipsychotic drugs recently introduced, and currently under development, has been based predominantly on dopamine and serotonin hypotheses of schizophrenia.
The drugs were selected primarily for their antagonist actions at dopamine and serotonin receptors and their ability to antagonize dopamine-and serotoninmediated effects in pharmacological screens. Since that strategy of drug development has apparently not yielded an antipsychotic that is as efficacious as clozapine, it may be prudent to consider other hypotheses of schizophrenia to guide alternative strategies for the discovery of novel antipsychotic agents. In this regard, the NMDA receptor hypofunction hypothesis of schizophrenia may provide a novel theoretical framework for investigating mechanisms of action of antipsychotic drugs.
The NMDA receptor hypofunction hypothesis of schizophrenia
In early clinical investigations, the anesthetics PCP and ketamine were observed to induced a state resembling schizophrenia in 40-50% of individuals given the drugs. [43] [44] [45] [46] [47] [48] In the 1970s, the abuse of PCP was frequently associated with psychotic-like responses (for review see 49 ). In retrospective analyses of admission records from PCP-induced adverse reactions, there was little distinction between symptoms presented by these patients and acute psychotic reactions in schizophrenic patients. The discovery that ketamine and PCP are non-competitive antagonists of the NMDA receptor prompted the hypothesis that schizophrenia involves reduced NMDA receptor function. [49] [50] [51] [52] Competitive antagonists of the NMDA receptor also induced psychotomimetic effects, 53 further supporting the hypothesis that endogenous psychosis may result from reduced NMDA function.
Recent studies with healthy human volunteers demonstrated that ketamine induces a spectrum of responses that resemble positive, negative, and cognitive symptoms of schizophrenia. [54] [55] [56] Furthermore, in stabilized schizophrenic patients, ketamine can precipitate psychotic reactions that in some cases re-create specific psychotic symptoms experienced during active phases of their illness. [57] [58] [59] These recent studies confirm the early clinical investigations and provide convincing support for the hypothesis that symptoms of schizophrenia may be associated with NMDA receptor hypofunction.
The 'psychotomimetic' effects induced by NMDA antagonists and psychostimulants (eg amphetamine) are distinctly different. For example, unlike ketamine, single injections of amphetamine rarely induced psychotic reactions in healthy subjects. After repeated treatments, amphetamine can induced positive schizophrenic-like reactions in healthy individuals, such as paranoia and hostility, but the withdrawal responses and cognitive deficits induced by ketamine are not observed. 60, 61 Similarly, in schizophrenic patients, stimulants precipitate positive symptoms but do not induce negative or cognitive symptoms. 62 The ability of ketamine and other NMDA antagonists to induce a behavioral state that resembles several dimensions of schizophrenia suggests that paradigms involving assessment of behavioral and neurochemical consequences of NMDA antagonists administration may constitute valid experimental models of some aspects of schizophrenia.
Neurobiological consequences of NMDA antagonist administration
Ketamine and PCP block NMDA receptors by binding to a site within the calcium channel of the receptor. Although, this molecular action of ketamine and PCP is well documented, mechanisms responsible for translation of this cellular and molecular action into the psychotomimetic effects of the drugs are poorly understood. The electrophysiological consequences of systemic administration of ketamine are complex, with some regions showing inhibition and other regions exhibiting excitation that can progress to seizure-like activity. 47, 63, 64 By contrast, iontophoretic application of ketamine to neurons uniformly antagonizes NMDAevoked excitatory responses. [65] [66] [67] [68] The well documented ability of ketamine to inhibit excitatory actions of NMDA at the cellular level, and induce excitatory responses after systemic administration, suggests that the excitatory effects of ketamine result from disruption of inhibitory neural circuits (ie from disinhibition).
Consistent with excitatory effects demonstrated in electrophysiological investigations, NMDA antagonists have been observed to induce neuroanatomically selective activation of brain glucose utilization. In response to anesthetic doses of ketamine, increased 2-deoxyglucose (2-DG) uptake was observed in the hippocampus, and decreased uptake observed in the medial geniculate, inferior colliculus and isocortical regions. 69, 70 Since subanesthetic doses of ketamine induce schizophrenic-like reactions, we examined subanesthetic doses of the NMDA antagonist on 2-DG uptake in rats. Robust increases in 2-DG uptake were observed in specific hippocampal subregions, limbic cortical regions (medial prefrontal, cingulate, retrosplenial cortices), nucleus accumbens, anterior ventral thalamic nucleus, and basolateral nucleus of the amygdala. 71, 72 In addition, laminar patterns of 2-DG uptake in isocortical regions were dramatically altered. In contrast to the marked activation of limbic brain regions after subanesthetic doses of ketamine, 2-DG uptake was substantially reduced in the inferior colliculus, medial geniculate, and auditory cortex. The effects of subanesthetic doses of ketamine on 2-DG were almost identical to those induced by the more specific antagonist MK-801, 73, 74 indicating that the effects observed for ketamine were due to the NMDA antagonistic properties of the drug. These findings of increased functional activity in limbic regions, and decreased activity in sensory pathways, suggest a dramatic remodeling of functional circuitry in response to a subanesthetic dose of ketamine.
Functional imaging studies in humans after subanesthetic doses of ketamine have also shown neuroanatomically specific functional activation. Lahti et al 57 found that ketamine increased blood flow in the anterior cingulate cortex and Breier et al 75 demonstrated increased 18 F-flurodeoxyglucose (FDG) in the prefrontal cortex after infusion of subanesthetic doses of ketamine. Vollenweider et al 76, 77 observed global increases in FDG uptake in response to subanesthetic doses of ketamine, but found greater increases in prefrontal cortex in comparison to other regions. Thus, studies in rats and humans indicate that subanesthetic doses of ketamine can alter patterns of brain activity and suggest a functional neuroanatomical basis for psychotomimetic effects of reduced NMDA receptor function.
Potential mechanisms for NMDA antagonistinduced functional activation
One potential mechanism by which NMDA receptor antagonism could result in functional activation would be to reduce excitation of inhibitory neurons. In support of a disinhibitory action involving GABAergic transmission, NMDA receptors on hippocampal inhibitory interneurons were demonstrated to be more sensi-tive to an NMDA antagonist, in comparison to NMDA receptors on CA1 pyramidal neurons. 78 In addition, benzodiazepines, which potentiate GABA-mediated neurotransmission, are effective in reducing adverse emergence reactions following ketamine anesthesia. 79 However, ketamine-induced psychosis was not attenuated by subhypnotic doses of lorazepam, and cognitive deficits induced by ketamine were worsened by the benzodiazepine. 80 Thus, components of ketamineinduced behavioral effects may be due in part, but not wholly, to disinhibitory effects via reduced activity of GABA-containing neurons.
In addition to disinhibition of GABAergic neurons, reduced autoregulation of glutamate release by antagonism of presynaptic NMDA receptors is another potential mechanism for ketamine-induced functional activation. In support of this latter possibility, Liu and Moghaddam 81 found that local infusion of NMDA antagonists into the striatum and hippocampus increased extracellular glutamate, suggesting a tonic inhibitory role of NMDA receptors on glutamate release. Also, systemic administration of ketamine and PCP increased glutamate release in the prefrontal cortex. 82, 83 
Effects of antipsychotic drugs on responses to NMDA antagonists in preclinical paradigms

Effects of typical and atypical drugs on neurotoxicological and behavioral responses to NMDA antagonists
There is an increasing body of evidence that atypical antipsychotic drugs can antagonize effects of ketamine and other NMDA antagonists. Although ketamine and the more selective NMDA antagonist MK-801 have neuroprotective effects in ischemic conditions, these drugs can induce neuronal damage in select brain regions. [87] [88] [89] Both typical and atypical antipsychotic drugs can antagonize MK-801-induced neurotoxic responses. 90, 91 In addition, MK-801-induced locomotor activation can be blocked by typical and atypical antipsychotics. [92] [93] [94] However, certain behavioral responses induced by NMDA antagonists are differentially affected by atyptical drugs. For example, clozapine and olanzapine blocked PCP-induced deficits in social interactions, whereas haloperidol and risperidone were ineffective. 92 Also, clozapine, quetiapine and olanzapine blocked NMDA antagonists-induced deficits in prepulse inhibition. [95] [96] [97] While both typical and atypical antipsychotics can reverse disrupting effects of dopamine agonists on prepulse inhibition, 98 the typical drugs do not block effects of NMDA antagonists in this paradigm. 99 
Differential effects of typical and atypical antipsychotics on NMDA antagonist-induced alterations in brain metabolic activity
We have demonstrated dramatic differences in the effects of clozapine in comparison to other antipsychotic drugs on ketamine-induced alterations in 2-DG uptake. Clozapine blocked the effects of the NMDA antagonist on 2-DG uptake in all brain regions, whereas haloperidol did not block, and in fact potentiated the metabolic activation in most brain regions. 71 Pretreatment of rats with risperidone did not block the effects of ketamine on 2-DG uptake, but unlike haloperidol, did not potentiate the effects of the NMDA antagonist. 100 In preliminary studies, olanzapine (5 mg kg −1 ) effectively blocked ketamine-induced increases in 2-DG uptake in the medial prefrontal cortex, but not in the hippocampus (Duncan et al, unpublished  observations) . However, at a dose of 10 mg kg −1 olanzapine blocked the effects of ketamine in all brain regions. At a dose of 5 mg kg −1 of olanzapine, there would be a maximally effective blockade of 5HT2 and D2 receptors. 101 Therefore an action of olanzapine other than D2 or 5HT2 receptor blockade may be involved in the drug's effect on ketamine-induced 2DG uptake. The results we have obtained with different classes of antipsychotic drugs suggest that the paradigm of ketamine-induced alterations in brain 2-DG uptake may constitute a promising model to explore mechanisms of action of atypical antipsychotic drugs, and to discriminate drugs with clozapine-like properties.
Differential effects of typical and atypical antipsychotics on electrophysiological responses to NMDA and NMDA antagonists
Electrophysiological studies examining the effects of clozapine indicate that the atypical antipsychotic may potentiate NMDA-mediated responses. Clozapine was shown to potentiate electrophysiological activation of neurons in the medial prefrontal cortex induced by stimulation of the forceps minor of the corpus callosum. 102 By contrast, haloperidol inhibited responses in the same experimental paradigm. These data are consistent with the opposite effects of colzapine on ketamine-induced 2-DG uptake. However, when effects of haloperidol and clozapine were examined on responses induced by direct application of NMDA, both haloperidol and clozapine potentiated NMDAevoked responses, although clozapine was more potent in this action. 102 The differential effects observed in the NMDA-evoked responses, in comparison to excitation induced by stimulation of the corpus callosum, was explained by the observation that haloperidol, but not clozapine, inhibited AMPA-activated responses.
In accord with the action of clozapine to potentiate NMDA-evoked electrophysiological responses are the findings that the atypical antipsychotic was able to reverse the inhibitory effect of PCP in the prefrontal cortex. 103 However, haloperidol and raclopride (a potent D2 antagonist) did not prevent the PCP-induced inhibition of NMDA-mediated electrophysiological activation. 103 These electrophysiological findings are consistent with the ability of clozapine (but not haloperidol) to block ketamine-induced increases in 2-DG uptake.
Potential mechanisms for clozapine-induced alterations in responses to NMDA antagonists
Further study is required to determine whether the action of clozapine to alter brain metabolic and electrophysiological effects induced by NMDA antagonists results from direct modulatory actions on NMDA receptors, or involves interactions with other neurochemical systems and circuits. Although there is no evidence for direct effects of clozapine on MK-801 binding, Banerjee et al 104 found that clozapine enhanced glycine-stimulated MK-801 binding to striatal membranes, indicating that the drug could potentiate NMDA-induced responses. Haloperidol produced a similar effect so it is difficult to explain the differences in clinical and preclinical effects of these prototype typical and atypical antipsychotic drugs by that action. It will be of interest to compare effects of different antipsychotics on glycine-stimulated MK-801 binding in regions other than the striatum, such as medial prefrontal cortex and hippocampus.
In regard to the observed effects of clozapine on electrophysiological responses to NMDA and PCP, the selective 5HT2A receptor antagonist M100907 produces similar effects as clozapine. 103 Those data suggest that the 5HT2A antagonistic properties of clozapine could account for the observed electrophysiological effects of the drug. Results of ongoing clinical trials with M100907 will determine the therapeutic potential of selective 5HT2A antagonism for schizophrenia.
The ability of clozapine to block the brain metabolic effects of ketamine in vivo may not relate directly to 5HT2A antagonism, since risperidone did not mimic the effects of clozapine in that paradigm. 100 However, it is possible that the 5HT2A blocking properties of clozapine contribute to its action, perhaps in concert with other pharmacological properties of the drug. Assessment of the effects of M100907, alone and in combination with other drugs selective for specific dopamine and serotonin receptors, could resolve the importance of various receptor-blocking properties of clozapine on the robust antagonism of ketamine-induced metabolic activation.
Effects of clozapine and haloperidol on responses to ketamine in schizophrenia patients
Although limited information is available from human studies, reported effects of antipsychotic drugs on responses to ketamine in schizophrenic patients are consistent with results from experimental animals, indicating that clozapine selectively modifies responses to NMDA antagonists. Patients on haloperidol exhibited greater increases in ketamine-induced psychosis ratings relative to baseline, compared to a haloperidol-free condition. 58 By contrast clozapine treatment blunted ketamine-induced increases in thought disturbance in schizophrenic patients. 105 These findings in humans parallel the observed effects of haloperidol and clozapine on responses to NMDA antagonists in preclinical models, and provide support for the contention that such preclinical paradigms may have utility for understanding the therapeutic basis of atypical antipsychotic drugs action.
Therapeutic potential of agonists of the glycine site on the NMDA receptor in schizophrenia patients
Glycine is a positive allosteric modulator and co-agonist at the NMDA receptor (for review see 106 ). The allosteric glycine regulatory site on the NMDA receptor represents a potential target for drugs to augment NMDA-mediated neurotransmission. There have been a number of clinical studies to test effects of different glycine site agonists in schizophrenic patients. The earliest studies in this regard used glycine in doses of 5-15 g day −1 and obtained inconsistent results. 107, 108 In more recent work with glycine, higher doses were administered (30-60 g day −1 ) and more robust and consistent effects were found, primarily in the improvement of negative symptoms. [109] [110] [111] d-Cycloserine, a partial agonist at the glycine regulatory site on the NMDA receptor, has also been tested in schizophrenic patients. In a very narrow dose range, d-cycloserine was demonstrated to improve negative symptoms when administered alone 112 and when added to conventional neuroleptic treatment regimes. 113, 114 However, when d-cycloserine was administered in conjunction with clozapine, the negative symptoms of the patients were worsened. 115, 116 A similar worsening of negative symptoms in schizophrenic patients who were treated with clozapine was observed after administration of glycine. 117 Defining mechanisms that account for the worsening of negative symptoms after administration of glycine and d-cycloserine to clozapine-treated patients could contribute to the understanding of clozapine's therapeutic mechanism of action.
The poor penetration of the blood-brain barrier by glycine, and the partial agonistic properties of d-cycloserine, make these agents less than optimal for providing pharmacological agonism of the glycine regulatory site on the NMDA receptor. d-Serine is a full agonist of the glycine regulatory site 118 and has recently been demonstrated to improve both positive and negative symptoms when given in conjunction with antipsychotic medication in treatment-resistant patients. 119 These data, together with the results of the clinical investigations with glycine and d-cycloserine, offer promise for the therapeutic potential of enhancing NMDA receptor function as a strategy for the pharmacotherapy of schizophrenia.
Conclusions
A number of antipsychotic drugs designated as 'atypical' have been introduced, or are in advanced stages of clinical development. The rationale for the development of these drugs was to mimic the favorable actions of clozapine, while minimizing its adverse side effects. The discovery strategy which led to this new and emerging class of atypical drugs has been based largely on antagonistic activity at D2 and 5HT2A receptors.
Although insufficient data are available to reach definitive conclusions, the clinical experience with risperidone and olanzapine to date suggests that neither drug is as efficacious as clozapine in treatment-resistant schizophrenic patients. Risperidone and olanzapine are highly effective antipsychotics with low EPS liability at appropriate doses, but available data suggest that these new 'atypical' drugs are not as effective as clozapine. 13, 35, 120 Since olanzapine and risperidone are potent antagonists at D2 and 5HT2 receptors, it is unlikely that those same properties of clozapine account for its superior therapeutic efficacy. There is currently insufficient clinical data to compare efficacy of clozapine with the newer 'atypicals' such as ziprasidone, M-100907, and quetiapine.
A growing body of data implicates involvement of NMDA receptors in the etiology of schizophrenia and mechanisms of action of clozapine. Exploration of the effects of antipsychotic drugs in experimental animal and human models of reduced NMDA receptor function may be useful for defining mechanisms of atypical antipsychotic drug action, and distinguishing drugs with clozapine-like qualities. Furthermore, if reduced NMDA receptor function is a component of the pathophysiology of schizophrenia, new therapeutic approaches could involve potentiating NMDAmediated responses using allosteric modulators such as glycine site agonists 119, 121, 122 or other approaches such as inhibition of glycine uptake. 123 
